Topic Review
Carbon Fiber Implants in Orthopaedic Oncology
Carbon fiber offers numerous material benefits including reduced wear, high strength-to-weight ratio, a similar elastic modulus to that of bone, and high biocompatibility. Carbon fiber implants are increasingly used in multiple arenas within orthopaedic surgery, including spine, trauma, arthroplasty, and oncology. In the orthopaedic oncologic population, the radiolucency of carbon fiber facilitates post-operative imaging for tumor surveillance or recurrence, the monitoring of bony healing and union, and radiation mapping and delivery.
  • 732
  • 12 Oct 2022
Topic Review
LncRNAs HOTAIR in BC therapy
Breast cancer (BC) is the most common cancer type among women, and morbidity and mortality rates are still very high. Despite new innovative therapeutic approaches for all BC molecular subtypes, the discovery of new molecular biomarkers involved in tumor progression has been fundamental for the implementation of personalized treatment strategies and improvement of patient management. Many experimental studies indicate that long non-coding RNAs (lncRNAs) are strongly involved in BC initiation, metastatic progression, and drug resistance. In particular, aberrant expression of HOX transcript antisense intergenic RNA (HOTAIR) lncRNA plays an important role in BC contributing to its progression and represents a predictor of BC metastasis. For its proven prognostic value, HOTAIR could represent a potential therapeutic target in BC.
  • 731
  • 22 Oct 2020
Topic Review
Management of Radiation Dermatitis for Breast Cancer Patients
The importance of holistic, patient-centered assessments, interventions, and education during RT should not be understated in its value of promoting patients’ physical and emotional comfort. The implementation of a skin care plan is an opportunity for patients to fully engage in self-care, not only promoting their skin health, reducing RT-associated side effects, and promoting the restoration of skin integrity, but can enhance their sense of control with the stressful context of cancer treatments. Ultimately, a patient-centered approach with implementation of a skin care plan may avert a delay in treatment or discontinuation of RT due to RD and afford breast cancer patients the greatest chance for long-term survival.
  • 731
  • 07 Nov 2022
Topic Review
Cancer Stem Cells in CRC
Cancer stem cells (CSCs) fuel tumor growth, metastasis and resistance to therapy in colorectal cancer (CRC). These cells therefore represent a promising target for the treatment of CRC. This review addresses the complexity of studying CSCs in CRC research and developing clinically effective treatments to enable CRC patients to achieve a short and long-term therapeutic response.
  • 730
  • 23 Jun 2021
Topic Review
Tunneling Nanotubes for Glioblastoma Treatment
Communication between cells helps tumors acquire resistance to chemotherapy and makes the struggle against cancer more challenging. Tunneling nanotubes (TNTs) are long channels able to connect both nearby and distant cells, contributing to a more malignant phenotype. This finding might be useful in designing novel strategies of drug delivery exploiting these systems of connection. This would be particularly important to reach tumor niches, where glioblastoma stem cells proliferate and provoke immune escape, thereby increasing metastatic potential and tumor recurrence a few months after surgical resection of the primary mass. Along with the direct inhibition of TNT formation, TNT analysis, and targeting strategies might be useful in providing innovative tools for the treatment of this tumor.
  • 730
  • 29 Mar 2022
Topic Review
Cytoskeleton Reorganization in EndMT
EndMT-derived cells, known as the myofibroblasts or cancer-associated fibroblasts (CAFs), are characterized by the loss of cell–cell junctions, loss of endothelial markers, and gain in mesenchymal ones.
  • 729
  • 16 Nov 2021
Topic Review
Radiation Responses in Tumour Microenvironment
Radiotherapy (RT) is a primary treatment modality for a number of cancers, offering potentially curative outcomes. Despite its success, tumour cells can become resistant to RT, leading to disease recurrence. Components of the tumour microenvironment (TME) likely play an integral role in managing RT success or failure including infiltrating immune cells, the tumour vasculature and stroma. Furthermore, genomic profiling of the TME could identify predictive biomarkers or gene signatures indicative of RT response.
  • 729
  • 06 Mar 2021
Topic Review
Small-Cell Lung Cancer
Small-cell lung cancer (SCLC) is an aggressive type of cancer with an incidence of about 15% among lung cancers and has a very poor prognosis due to its rapid development of resistance to chemo- and radiotherapies. Unlike the increase in personalized approaches to the clinical care of patients with non-small-cell lung cancer (NSCLC), clinical protocols for SCLC still mainly depend on the stage of the disease, prior therapies, and lack of specific molecular support. This approach was mainly due to the idea of SCLC as a monolithic entity with common genetic features, which was strictly linked to the lack of an adequate quantity of tissue samples in this inoperable class of patients, for the lack of a clear and comprehensive biological profile presented an obstacle.
  • 729
  • 22 Sep 2021
Topic Review
Lipids in Immunity to Cancer
While immunotherapies for diverse types of cancer are effective in many cases, relapse is still a lingering problem. Like tumor cells, activated immune cells have an anabolic metabolic profile, relying on glycolysis and the increased uptake and synthesis of fatty acids. In contrast, immature antigen-presenting cells, as well as anergic and exhausted T-cells have a catabolic metabolic profile that uses oxidative phosphorylation to provide energy for cellular processes. One goal for enhancing current immunotherapies is to identify metabolic pathways supporting the immune response to tumor antigens. A robust cell expansion and an active modulation via immune checkpoints and cytokine release are required for effective immunity. Lipids, as one of the main components of the cell membrane, are the key regulators of cell signaling and proliferation. Therefore, lipid metabolism reprogramming may impact proliferation and generate dysfunctional immune cells promoting tumor growth. Based on lipid-driven signatures, the discrimination between responsiveness and tolerance to tumor cells will support the development of accurate biomarkers and the identification of potential therapeutic targets. These findings may improve existing immunotherapies and ultimately prevent immune escape in patients for whom existing treatments have failed
  • 728
  • 04 Nov 2020
Topic Review
Strategies for Identification of Neoantigens
This entry provides an overview of currently available approaches applied for neoantigens discovery—tumor-specific peptides that appeared due to the mutation process and distinguish tumors from normal tissues. Focusing on genomics-based approaches and computational pipelines, we cover all steps required for selecting appropriate candidate peptides starting from NGS-derived data. Moreover, additional approaches such as mass-spectrometry-based and structure-based methods are discussed highlighting their advantages and disadvantages. This review also provides a description of available complex bioinformatics pipelines ensuring automated data processing resulting in a list of neoantigens. We propose the possible ideal pipeline that could be implemented in the neoantigens identification process. We discuss the integration of results generated by di erent approaches to improve the accuracy of neoantigens selection.
  • 728
  • 08 Apr 2021
Topic Review
Boron Neutron Capture Therapy
Boron neutron capture therapy (BNCT) is a type of targeted radiotherapy. BNCT shows promising results in treating lung cancer, recurrent head and neck cancer, sarcomas, and high grade brain tumors.
  • 728
  • 29 Nov 2021
Topic Review
Drug Repurposing in Prostate Cancer
Prostate cancer (PCa) is the second most common cancer in men. Common treatments include active surveillance, surgery, or radiation. Androgen deprivation therapy and chemotherapy are usually reserved for advanced disease or biochemical recurrence, such as castration-resistant prostate cancer (CRPC), but they are not considered curative because PCa cells eventually develop drug resistance. The need for novel therapeutic approaches is necessary under these circumstances. An alternative way to treat PCa is by repurposing of existing drugs that were initially intended for other conditions.
  • 728
  • 02 Mar 2022
Topic Review
Translational Formulation Technologies for Cancer-Therapy
Over the past few decades, the field of cancer therapy has seen a significant change in the way in which formulations are designed and developed, resulting in more efficient products that allow us to ultimately achieve improved drug bioavailability, efficacy, and safety. However, although many formulations have entered the market, many others have fallen by the wayside leaving the scientific community with several lessons to learn.
  • 728
  • 16 Nov 2020
Topic Review
Peptide-Based Vaccines for Breast Cancer
Breast cancer (BC) is the main type of cancer in women and the second most frequent cancer worldwide. The conventional treatment includes surgery, chemotherapy, hormonal therapy, and immunotherapy. This immunotherapy is based on administering monoclonal therapeutic antibodies (passive) or vaccines (active) with therapeutic purposes. Tumor antigens are classified as tumor-associated antigens (TAAs) and tumor-specific antigens (TSA). New TAAs were proposed for the formulation of peptide-based vaccines, including MUC-1 (mucin-1), FRα (folate receptor alpha), members of the MAGE A family (melanoma-associated antigen), and EGFR (epidermal growth factor receptor).
  • 727
  • 26 Aug 2022
Topic Review
ICI-Based Combination Therapy for HCC
Advanced, unresectable hepatocellular carcinoma has a dismal outcome. Multiple immune checkpoint inhibitors (ICIs) targeting the programmed-cell death 1 pathway (PD-1/L1) have been approved for the treatment of advanced HCC. However, outcomes remain undesirable and unpredictable on a patient-to-patient basis. The combination of anti-PD-1/L1 with alternative agents, chiefly cytotoxic T-lymphocyte antigen-4 (CTLA-4) ICIs or agents targeting other oncogenic pathways such as the vascular endothelial growth factor (VEGF) pathway and the c-MET pathway, has, in addition to the benefit of directly targeting alterative oncogenic pathways, in vitro evidence of synergism through altering the genomic and function signatures of T cells and expression of immune checkpoints. Several trials have been completed or are underway evaluating such combinations. Finally, studies utilizing transcriptomics and organoids are underway to establish biomarkers to predict ICI response. 
  • 726
  • 06 May 2021
Topic Review
Tumor-Associated Trypsin Inhibitor (TATI)
TATI, also known as pancreatic secretory trypsin inhibitor (PSTI) or serine peptidase inhibitor Kazal 1 type (SPINK1), is a trypsin inhibitor that functions mainly in the pancreas, where it serves as a suppressor of premature trypsinogen activation.
  • 726
  • 22 Sep 2021
Topic Review
Molecular Markers and Targets in Melanoma
Melanoma develops as a result of several genetic alterations, with UV radiation often acting as a mutagenic risk factor. Deep knowledge of the molecular signaling pathways of different types of melanoma allows better characterization and provides tools for the development of therapies based on the intervention of signals promoted by these cascades. The latest World Health Organization classification acknowledged the specific genetic drivers leading to melanoma and classifies melanocytic lesions into nine distinct categories according to the associate cumulative sun damage (CSD), which correlates with the molecular alterations of tumors. The largest groups are melanomas associated with low-CSD or superficial spreading melanomas, characterized by frequent presentation of the BRAFV600 mutation. High-CSD melanomas include lentigo maligna type and desmoplastic melanomas, which often have a high mutation burden and can harbor NRAS, BRAFnon-V600E, or NF1 mutations. Non-CSD-associated melanomas encompass acral and mucosal melanomas that usually do not show BRAF, NRAS, or NF1 mutations (triple wild-type), but in a subset may have KIT or SF3B1 mutations. To improve survival, these driver alterations can be treated with targeted therapy achieving significant antitumor activity.
  • 726
  • 22 Apr 2022
Topic Review
Atypical Endometriosis-Associated Biomarkers
Ovarian endometriosis may increase the risk of malignancy. Several studies have suggested atypical endometriosis as the direct precursor of endometriosis-associated ovarian cancer. Atypical endometriosis can be a transitioning entity from endometriosis to endometriosis-associated ovarian cancers. 39 studies assessing numerous molecular targets of AE, such as immunohistochemical expression of BAF250, PIK3CA, PTEN, HNF-1beta, ER, and PR. Unfortunately, these molecular biomarkers of AE require expensive molecular analysis, histological examination is always needed, and none of them has such strong evidence to justify their systematic use in the management of the neoplastic risk of endometriosis. Further studies are needed to validate evidence on available biomarkers for the presence of AE, which is a high oncologic risk condition. Moreover, the introduction of novel serum biomarkers could be useful for the non-invasive diagnosis of AE.
  • 726
  • 05 May 2022
Topic Review
Oxaliplatin-Induced Peripheral Neuropathy
Oxaliplatin-induced peripheral neurotoxicity (OIPN) is a severe and potentially permanent side effect of cancer treatment affecting the majority of oxaliplatin-treated patients, mostly with the onset of acute symptoms, but also with the establishment of a chronic sensory loss that is supposed to be due to dorsal root ganglia neuron damage. The pathogenesis of OIPN is still largely unknown. This lack of information is a limitation in the identification of effective strategies to prevent or limit OIPN incidence and severity. So far, no treatment is available for the prevention of OIPN, although duloxetine showed moderate evidence of efficacy in the reduction of OIPN symptoms. On this background, several neuroprotection clinical trials are ongoing in oxaliplatin-treated patients, although only part of them relies on solid preclinical evidence supporting the study hypothesis. Based on the available literature it can be concluded that dose and schedule modification is currently the most effective approach to limit the severity of OIPN since pharmacological prevention and treatment of OIPN still remains an unmet clinical need.
  • 726
  • 26 Oct 2020
Topic Review
Breast-Conserving Surgery
Breast-conserving surgery’s main goal is to fully remove the tumor with clear margins, while avoiding resection of healthy breast tissue in order to achieve better cosmetic results. 
  • 726
  • 22 Feb 2021
  • Page
  • of
  • 128
ScholarVision Creations